SARS-CoV
SARS coronavirus
SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).
CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.
All Product Categories
-
SARS-CoV Related Products (1208)
Related Products (1208)
-
Recombinant Proteins (196)
-
TAPI-2 (Standard)
0 ImagesCat. No.: HY-100211RCAS No.: 187034-31-7Synonyms: TNF Protease Inhibitor 2 (Standard)TAPI-2 (Standard) is the analytical standard of TAPI-2 (HY-100211). This product is intended for research and analytical applications. TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM), with an IC50 of 20 μM for MMP. TAPI-2 blocks the entry of infectious SARS-CoV.
-
F594-1001
0 ImagesCat. No.: HY-160943CAS No.: 1215326-44-5F594-1001 (compound 6) is a potent and highly selective SARS-CoV-2 Mac1-ADP-ribose inhibitor with IC50s of 8.5 μM, 68 μM and 45 μM for SARS-CoV-2 in AS, FP, and FRET assays, respectively. F594-1001 directly binds to SARS-CoV-2 Mac1 and exhibits a dose-dependent inhibition of Mac1 ADP-ribosylhydrolase activity.
-
SARS-CoV-2-IN-102
0 ImagesCat. No.: HY-168584CAS No.: 3055041-73-8
-
SARS-CoV-2 PLpro-IN-4
0 ImagesCat. No.: HY-181262SARS-CoV-2 PLpro-IN-4 is a SARS-CoV-2 papain-like protease (PLPro) inhibitor with an IC50 of 0.4 μM. SARS-CoV-2 PLpro-IN-4 binds to the S3 and S4 pockets of SARS-CoV-2 PLPro, thereby functionally inhibiting its activity. SARS-CoV-2 PLpro-IN-4 exhibits antiviral activity and can be used in research on COVID-19.
-
Boceprevir (Standard)
0 ImagesSynonyms: EBP 520 (Standard); SCH 503034 (Standard)Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 3CLpro activity.
-
Bardoxolone (Standard)
0 ImagesSynonyms: CDDO (Standard); RTA 401 (Standard)Bardoxolone (Standard) is the analytical standard of Bardoxolone (HY-14909). This product is intended for research and analytical applications. Bardoxolone is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury.
-
EIDD-1931-d2
0 ImagesCat. No.: HY-125033S1CAS No.: 1955549-12-8Synonyms: β-D-N4-hydroxycytidine-d2; NHC-d2EIDD-1931-d2 is the deuterium labeled 3,6-Dichloro-2-methoxybenzoic acid.
-
(S)-Hydroxychloroquine sulfate
0 ImagesCat. No.: HY-145530CAS No.: 155204-09-4Synonyms: (S)-HCQ sulfate(S)-Hydroxychloroquine ((S)-HCQ) sulfate is an isomer of Hydroxychloroquine (HY-W031727). (S)-Hydroxychloroquine sulfate (2.5-20 mg/mL) reduces the rate of insulin degradation in liver homogenates isolated from non-diabetic and diabetic rats. Formulations containing Hydroxychloroquine have been used in the study of malaria, rheumatoid arthritis, and systemic lupus erythematosus.
-
Paquinimod-d5
0 ImagesCat. No.: HY-100442SSynonyms: ABR-215757-d5; ABR 25757-d5Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.
-
SCHEMBL12616233
0 ImagesCat. No.: HY-183661CAS No.: 910644-11-0SCHEMBL12616233 is a SARS-CoV-2 main protease (MPro) inhibitor. SCHEMBL12616233 binds to the active cavity of SARS-CoV-2 MPro and forms a stable complex. SCHEMBL12616233 can be used for the research of covid-19.
-
(Rac)-Z-FA-FMK
0 ImagesCat. No.: HY-123185CAS No.: 96922-64-4(Rac)-Z-FA-FMK is the racemate of Z-FA-FMK. (Rac)-Z-FA-FMK is an inhibitor of cathepsin B with a Ki of 1.5 μM. (Rac)-Z-FA-FMK inhibits caspase-2, -3, -6, -7, and -9 with IC50s of 6.147, 15.41, 32.45, 9.077, and 110.7 μM. (Rac)-Z-FA-FMK inhibits the main protease of SARS-CoV-2 replication with an IC50 of 11.39 μM. (Rac)-Z-FA-FMK inhibits the increased IL-1β level induced by LPS and NF-κB transactivation in macrophages.
-
Mpro/Cathepsin L-IN-2
0 ImagesCat. No.: HY-176229Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2 main protease (Mpro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections.
-
Atazanavir (Standard)
0 ImagesSynonyms: BMS-232632 (Standard)Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
-
PIKfyve-IN-5
0 ImagesCat. No.: HY-189387PIKfyve-IN-5 is a PIKfyve inhibitor (IC50 = 32 nM) with selective antiviral activity. PIKfyve-IN-5 inhibits PIKfyve and blocks the release of the viral genome from endosomes into the cytosol by sequestering viral particles within swollen spherical vacuoles. PIKfyve-IN-5 exhibits antiviral activity against SARS-CoV-2 in human lung epithelial cells. PIKfyve-IN-5 can be used for research on SARS-CoV-2 infection.
-
SARS-CoV-2-IN-120
0 ImagesCat. No.: HY-180129CAS No.: 308293-08-5SARS-CoV-2-IN-120 (Compound S22) is a SARS-CoV-2-specific entry inhibitor. SARS-CoV-2-IN-120 binds and trimerizes within the apex cavity of the SARS2 spike trimer. SARS-CoV-2-IN-120 blocks RBD-ACE2 interaction. SARS-CoV-2-IN-120 neutralizes BA.2 and subsequent Omicron variants. SARS-CoV-2-IN-120 inhibits SARS-CoV-2 replication in mice.
-
SARS-CoV-2 Mpro-IN-46
0 ImagesCat. No.: HY-175015CAS No.: 1800004-01-6
-
K22
0 ImagesK22 is an anti-Coronaviral compound. K22 reduces double-stranded RNA. K22 displays antiviral activity beyond the Coronavirinae subfamily, namely against nidoviruses of the Torovirinae subfamily (EToV and WBV) and members of the Arteriviridae family (PRRSV, EAV). K22 displays antiviral activity against HCoV-229E.
